Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073

UNC Libraries(2020)10.17615/5mda-3h63Source: DataRank Database

Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073 is a research paper published in UNC Libraries (2020). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.03)OA: greenTopics (48)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Scott Rose ORCID,Sheldon D. Fields ORCID,Lynda Emel ORCID,Marc Siegel ORCID,Geetha Beauchamp ORCID

Live enrichment

PubMed:21097893 OpenAlex:https://openalex.org/W4301426309

National Institutes of Health

Grant: 3UM1AI068617-20S1

HPTN SDMC: HPTN 096 Getting to Zero among Highest HIV Incidence (HHI) Men who have Sex with Men (MSM) in the American South: Testing an Integrated Strategy

National Institutes of Health

Grant: 5UM1AI068613-16

LC: HIV PREVENTION TRIALS NETWORK

National Institutes of Health

Grant: 5UM1AI068619-09

LOC: HIV Prevention Trials Network

FWCI

0.03

Citation Percentile

0.4%

Citation Trend

2020

greenLicense: ASM Journals Non-Commercial TDM

repositoryhttps://doi.org/10.17615/5mda-3h63

https://doi.org/10.1128/aac.02743-16

https://aac.asm.org/content/aac/61/7/e02743-16.full.pdf

https://dx.doi.org/10.17615/5mda-3h63

https://pubmed.ncbi.nlm.nih.gov/28438932

Fields of Study

HIV/AIDS Research and InterventionsHIV-related health complications and treatmentsPneumocystis jirovecii pneumonia detection and treatment03 medical and health sciences0302 clinical medicine

Keywords

Human immunodeficiency virus (HIV)RegimenMedicineClinical trialIntensive care medicinePharmacologyImmunologyInternal medicineMaleAnti-HIV AgentsClinical Sciencespreexposure prophylaxisDrug Resistance610HIV InfectionsMicrobiologyMedication AdherenceDrug Resistance, Multiple, Viral616EmtricitabineHumansViraladherenceTenofovir Disoproxil Fumarate Drug CombinationTruvadaTenofovirHPTN 073Biomedical and Clinical SciencesPreventionEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHIVPharmacology and Pharmaceutical SciencesMedical microbiologyInfectious DiseasesGood Health and Well Being5.1 PharmaceuticalsHIV/AIDSSexually Transmitted Infectionsantiretroviral drugPre-Exposure ProphylaxisAntimicrobial ResistanceInfectionMultiple

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being